HHS Perinatal Antiretroviral Guidelines Updated
AIDSinfo announces the release of the updated Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States.
Key updates to the guidelines include:
- New recommendation on use of antiretroviral therapy (ART) for serodiscordant couples who want to conceive, with strength of the recommendation differing on the basis of the infected partner’s CD4-cell count.
- Added discussion of the pre-exposure prophylaxis (PrEP) studies in heterosexual couples, with a new recommendation regarding PrEP in discordant couples who want to conceive.
- Added discussion on benefit of therapy for reducing sexual transmission to discordant partners when viral suppression is maintained.
- Reclassification of various antiretroviral (ARV) agents to the categories of Preferred Agents, Alternative Agents, or for Use in Special Circumstances.
- Increased discussion on timing (that is, trimester) of initiation of ARV drugs in ARV-naive pregnant women.
- Discussion of continuation of efavirenz in women receiving efavirenz-based ART who present for antenatal care in the first trimester.
- Addition of a new table: Table 7 – Results of Studies Assessing Association Between Antiretroviral Regimens and Preterm Delivery.
- Discussion of use of intravenous (IV) zidovudine during labor and maternal viral load, with recommendation that IV zidovudine is needed only for women with HIV RNA ≥400 copies/mL (or unknown HIV RNA) near delivery.
- Updated information and discussion concerning infant ARV prophylaxis in the context of the NICHD-HPTN 040 study.
- New recommendations regarding postnatal care of the HIV-exposed neonate.
For a complete preview of updates to the guidelines, see What’s New in the Guidelines?
To view or download the guidelines, go to the Perinatal Guidelines section of AIDSinfo. (A separate PDF file of all tables in the guidelines can also be downloaded from the page.) To request a printed copy of the guidelines, e-mail ContactUs@aidsinfo.nih.gov.
Submit Feedback on the Perinatal ARV Guidelines
The HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission welcomes feedback on the updated Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Please send your comments with the subject line "Comments on Perinatal ARV Guidelines" to ContactUs@aidsinfo.nih.gov by August 14, 2012.